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Abstract
Background Alirocumab is a fully human monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9) 
and has been previously shown, in the phase III ODYSSEY clinical trial program, to provide significant lowering of low-
density lipoprotein cholesterol (LDL-C) and reduction in risk of major adverse cardiovascular events. However, real-world 
evidence to date is limited.
Objective The primary objective was to describe baseline characteristics, clinical history, and prior lipid-lowering therapy 
(LLT) use of patients initiated on alirocumab in UK clinical practice following publication of health technology appraisal 
(HTA) body recommendations. Secondary objectives included description of alirocumab use and lipid parameter outcomes 
over a 4-month follow-up period.
Methods In this retrospective, single-arm, observational, multicenter study, data were collected for 150 patients initiated 
on alirocumab.
Results Mean (standard deviation; SD) age of patients was 61.4 (10.5) years and baseline median (interquartile range; IQR) 
LDL-C level was 4.8 (4.2–5.8) mmol/l. Alirocumab use occurred predominantly in patients with heterozygous familial 
hypercholesterolemia (HeFH) (n = 100/150, 66%) and those with statin intolerance (n = 123/150, 82%). Most patients started 
on alirocumab 75 mg (n = 108/150 [72%]) and 35 (23.3%) were up-titrated to 150 mg. Clinically significant reductions in 
atherogenic lipid parameters were observed with alirocumab, including LDL-C (median [IQR] change from baseline, − 53.6% 
[− 62.9 to − 34.9], P < 0.001).
Conclusion This study highlights the unmet need for additional LLT in patients with uncontrolled hyperlipidemia and dem-
onstrates the clinical utility of alirocumab in early real-world practice, where dosing flexibility is an important attribute of 
this therapeutic option.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s4080 1-019-00166 -7) contains 
supplementary material, which is available to authorized users.
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1 Introduction
Elevated LDL-C is a risk factor for cardiovascular disease 
(CVD), and its role in the pathogenesis of atherosclerosis is 
well established [1]. Importantly, it is the only lipid param-
eter shown to reduce the rate of CVD via targeted therapeu-
tic intervention [2–5].
Low-density lipoprotein receptors (LDLRs) are present 
on the surface of all cells, including hepatocytes, which are 
responsible for clearing circulating LDL-C. PCSK9 is an 
enzyme that binds to and promotes the degradation of LDLR, 
reducing LDL-C clearance [6, 7]. Alirocumab, a fully human 
immunoglobulin G1 monoclonal antibody, binds with high 
affinity and specificity to PCSK9, inhibiting its  binding 
to and intracellular degradation of LDLR; this in turn 
increases the amount of LDLR available to clear LDL-C, 
lowering plasma LDL-C concentrations [8–10].
The efficacy and safety of alirocumab have been exten-
sively investigated in the ODYSSEY phase III clinical trial 
program, including patients with HeFH as well as those 
with non-familial high-risk hypercholesterolemia [11]. Ali-
rocumab has demonstrated clinically meaningful LDL-C 
reductions in patients with a range of genetic variants causa-
tive of HeFH [6, 7].
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Results from the ODYSSEY trials supported the market-
ing authorization of alirocumab in adults with primary hyper-
cholesterolemia (heterozygous familial and non-familial) or 
mixed dyslipidemia as an adjunct to diet. Alirocumab is indi-
cated for use in combination with a statin, or statin with other 
lipid-lowering therapies (LLTs), in patients unable to attain 
LDL-C goals with the maximum tolerated dose of a statin 
alone or in combination with other LLTs in patients who are 
statin intolerant or for whom a statin is contraindicated [9].
The usual starting dose of alirocumab is 75 mg adminis-
tered subcutaneously once every 2 weeks (Q2W); however, 
patients requiring larger LDL-C reduction (> 60%) may be 
started on 150 mg Q2W or 300 mg monthly. Only the 75 mg 
and 150 mg strengths were available in the UK during the 
observation period of this study. Ongoing treatment is indi-
vidualized based on patient characteristics and response [9].
Following receipt of marketing authorization, alirocumab 
has been assessed by UK HTA bodies. The National Insti-
tute of Health and Care Excellence (NICE) recommends 
alirocumab as an option for treating certain patients with 
primary hypercholesterolemia or mixed dyslipidemia on 
maximally tolerated LLT based on their prior CVD event 
history and LDL-C concentrations [12]. The Scottish Medi-
cines Consortium (SMC) recommends specialist use only 
of alirocumab in patients at high cardiovascular risk, e.g., 
patients with HeFH and LDL-C ≥ 5.0 mmol/l, for primary 
prevention of cardiovascular events or patients with HeFH 
and LDL-C ≥ 3.5 mmol/l, for secondary prevention of cardi-
ovascular events or patients at high risk due to previous car-
diovascular events and LDL-C ≥ 4.0 mmol/l or patients with 
recurrent/polyvascular disease and LDL-C ≥ 3.5 mmol/l 
[13].
Subsequent to marketing authorization and HTA body 
recommendations, it is of interest to describe alirocumab 
use across UK clinical practice to understand the baseline 
profile of patients and prescribing patterns supporting future 
HTA discussion since, at publication, available evidence was 
from studies held in one or two UK centers only [14–16].
The primary objective of this study was to describe base-
line characteristics, clinical history, and prior LLT use of 
patients initiated on alirocumab in early UK clinical prac-
tice, following publication of HTA body recommendations. 
Secondary objectives were to describe alirocumab use (start-
ing dose and titration patterns), LLT use, and lipid meas-
urements over a 4-month post-initiation period. Change in 
lipid parameters from baseline to post-initiation was also 
observed as an exploratory end point.
2  Methods
This retrospective, observational, single-arm study was con-
ducted in ten National Health Service (NHS) centers across 
the UK. Sites were chosen from different geographical loca-
tions across England, Wales, and Scotland.
Anonymized patient-level data, corresponding to a prede-
fined core data set, were collected from electronic medical 
notes and paper charts and entered into a database. The data-
base was compliant with the Code of Federal Regulations 21, 
Part 11 [17], and approved for use in the NHS setting.
The study was conducted in accordance with the princi-
ples of the 18th World Medical Assembly (Helsinki, 1964) 
and all its subsequent amendments (up to 2013) [18], and 
with the International Society for Pharmacoepidemiology 
guidelines for Good Pharmacoepidemiology Practice [19], 
in accordance with local regulations, including local data 
protection regulations.
The study included patients aged ≥ 18 years initiated on 
alirocumab between May 2016 and July 2017. Patients who 
initiated on alirocumab ≥ 4 months before the date of data 
collection were included and were required to have made 
≥ 1 contact with the site within the post-initiation period.
Exclusion criteria were: enrollment in a trial while tak-
ing alirocumab, previous enrollment in PCSK9 inhibitor 
(PCSK9i) trial, pregnancy, or secondary causes of dyslipi-
demia (e.g., drug-induced, hypothyroidism, renal failure, 
nephrotic syndrome, and excessive alcohol usage).
To avoid selection bias, patients were recruited in reverse 
consecutive order from the last eligible patient seen dur-
ing the most recent clinic visit. A minimum target of 5 and 
a maximum of 30 eligible patients per center were chosen 
pragmatically to ensure geographical representation and to 
minimize potential for center bias (Online Resource 1). Data 
Key Points 
This study is the largest multicenter study of alirocumab 
in real-world UK clinical practice.
Early alirocumab use post-issuance of health technol-
ogy body recommendations predominantly occurred in 
patients with HeFH. Uptake of a novel therapeutic in this 
high-risk patient group and those with a large degree of 
statin intolerance highlights the previously unmet need 
for additional lipid-lowering treatment options.
Flexibility in dosing and the ability to adjust dose based 
on response and acceptability may be important when 
initiating a new treatment; a higher degree of alirocumab 
use at initiation with the 75 mg strength than the 150 mg 
strength was reported.
Clinically significant reductions in the lipid parameters, 
LDL-C, non-HDL-C, and total cholesterol observed with 
alirocumab in real-world practice were consistent with 
the phase III trial program.
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heterogeneity was evaluated using one-way analysis of vari-
ance (ANOVA) comparing baseline LDL-C levels between 
sites.
Data for cardiovascular event and statin-use history were 
collected at any point between primary hyperlipidemia diag-
nosis and alirocumab initiation. The most recently available 
measurements within a 6-month period prior to the initia-
tion of alirocumab were collated for the remainder of base-
line variables. Different data collection time periods were 
used for the various variables based on feasibility of being 
able to collect these data in routine real-world clinical prac-
tice. Additionally, HeFH diagnosis was made on clinical or 
genetic grounds since not all centers had access to genotyp-
ing facilities.
The post-initiation period was defined as the 4-month 
period following alirocumab initiation. Alirocumab starting 
dose, titration, and discontinuation, change in or discontinu-
ation of LLT, and lipid parameters were collected over this 
period. Statistical methods for lipid parameter analyses can 
be found in Online Resource 2.
Treatment discontinuation was captured and reasons 
recorded as follows: lack of efficacy, difficulty with dosing, 
difficulty with device, adverse events (AEs), or unknown.
Descriptive statistics were calculated for quantitative and 
qualitative variables and analyzed using STATA v14.2 (Stata-
Corp LLC, College Station, TX, USA). Although a descrip-
tive study, it was estimated that a sample size of 138 patients 
would be required to achieve a precision for the main base-
line parameter of interest (LDL-C), such that 95% confidence 
interval widths would be 0.5 mmol/l from the estimate of 
the mean assuming a standard deviation (SD) of 1.5 mmol/l. 
No formal power calculations for lipid outcomes were per-
formed. Additionally, a post hoc analysis assessed time to 
up-titration from alirocumab 75 mg to alirocumab 150 mg.
3  Results
An analysis of between-center heterogeneity comparing 
baseline LDL-C levels between sites found no significant 
difference (one-way ANOVA, P = 0.3), allowing pooling of 
patient data across centers.
Baseline characteristics, medical history, and clinical 
history of the cohort (n = 150) prior to alirocumab initia-
tion can be seen in Table 1. Mean age at baseline was 61.4 
(SD: 10.5) years, and 74 (49.3%) patients were male. Two-
thirds of patients had a HeFH diagnosis (either phenotype 
or genotype; n = 100 [66.7%]), 26 (17.3%) had primary non-
familial hypercholesterolemia, and 24 (16.0%) had mixed 
dyslipidemia. Mean body mass index (BMI) was 29.3 (SD: 
4.5), and 33 (37.5%) patients had a BMI of ≥ 30 kg/m2. 
However, these data were only available for 88 patients. 
Twenty-seven (18.0%) had a diabetes diagnosis. Patients 
had a median of one prior cardiovascular event (range 
0–12): 42 (28.0%) had previous myocardial infarction, 9 
(6.0%) had unstable angina, and 10 (6.7%) had peripheral 
artery disease. Additionally, alirocumab was known to be 
prescribed within the NICE/SMC recommendations in 67% 
of patients (n = 100).
When considering previous hyperlipidemia-related treat-
ment, patients had received a median of three statins since 
diagnosis (range 1–5; interquartile range [IQR] 2–4). Two-
thirds (n = 100 [66.7%]) were, in the opinion of the treat-
ing physician, intolerant to ≥ 2 statins. The most common 
reason for discontinuing or changing statin dose was due 
to AE (17/37 [45.9%]; Table 2). Overall, background LLT 
remained unchanged between the pre- and post-initiation 
periods; however, these data were sparsely recorded across 
sites.
On alirocumab initiation, 72.0% (n = 108) of patients 
received alirocumab 75 mg. Thirty-five (23.3%) patients 
were up-titrated to 150 mg. Two (1.3%) patients were up-
titrated to 150 mg and then subsequently down-titrated to 
75 mg over the observation period (reason not captured). 
Median time to up-titration was 11.7 (range 4.0–16.0; IQR 
8.0–12.9) weeks. Nineteen (12.7%) patients discontinued ali-
rocumab, most commonly because of AEs (17/19 [89.5%]; 
Table 3).
Median (IQR) LDL-C at baseline was 4.8 [4.2–5.8] 
mmol/l (reported for 94 [62.7%] patients who did receive 
any alirocumab dose change prior to measurement of a 
paired post-initiation LDL-C value). A median reduction 
in LDL-C to 2.3 (IQR 1.7–3.1) mmol/l post-alirocumab 
initiation was observed for the overall group (n = 94), 
equating to a median change of –53.6% from baseline 
(P < 0.001) (Fig. 1). Significant median [IQR] reductions 
in LDL-C were also observed both for the subgroup of 
patients who received alirocumab 75 mg (− 50.0% [− 60.0 
to − 32.8], P < 0.001) and those who received alirocumab 
150 mg (− 60.2% [− 69.8 to − 50.3], P < 0.001) (Table 4). 
Changes in other lipid parameters over the observation 
period can be seen in Fig. 1. Clinically significant reduc-
tions in non-HDL-C and total cholesterol were observed 
(P < 0.001), in line with the strength of alirocumab admin-
istered (Table 4).
4  Discussion
This is the largest multicenter study of alirocumab in real-
world UK clinical practice across a range of centers in the 
UK, following the publication of NICE and SMC recom-
mendations. Alirocumab use occurred predominantly in 
patients with HeFH, who were known to be at high risk 
of cardiovascular complications compared with the general 
population [20]. This observation together with the high 
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level of statin intolerance recorded in this study highlights 
the previously unmet need for treatment options after the 
failure of conventional hyperlipidemia treatment.
The high median baseline LDL-C level of the cohort 
(4.8 mmol/l) suggested that most patients would be initi-
ated on alirocumab 150 mg, according to recommendations 
in the Summary of Product Characteristics [9]. However, 
only 42 (28%) patients were initiated on the 150 mg strength. 
Additionally, given that most patients had a diagnosis of 
HeFH (n = 100/150 [66.7%]), we observed less frequent up-
titration from alirocumab 75 mg to 150 mg in the real world 
compared with some studies of these patients within the 
ODYSSEY phase III program [21]. Predominant initiation 
of alirocumab 75 mg compared with 150 mg may be attrib-
uted to clinician or patient preference, cautious prescribing 
because of limited experience of PCSK9i, or local prescrib-
ing guidelines implemented during the early period after 
the publication of HTA body recommendations. Despite the 
lower use of the higher strength of alirocumab (150 mg), 
a clinically significant reduction in LDL-C was observed, 
consistent with that seen in randomized clinical trials [11].
On alirocumab initiation, 108 (72.0%) patients received 
alirocumab 75 mg. Thirty-five (23.3%) patients were up-
titrated to 150 mg. Two (1.3%) patients were up-titrated 
Table 1  Baseline characteristics and medical history for UK patients 
initiated on alirocumab
Variable Cohort 
(N = 150)a
Diagnosis, n (%)
 Primary non-familial hypercholesterolemia 26 (17.3)
 Mixed dyslipidemia 24 (16.0)
 Primary HeFH (clinically or genetically defined) 100 (66.7)
Age, years
 Mean (SD) 61.4 (10.5)
Gender, n (%)
 Male 74 (49.3)
BMI, n 88
 Overall BMI, mean (SD) kg/m2 29.3 (4.5)
 Underweight (16 to < 18.5 kg/m2), n (%) 0 (0.0)
 Normal (18.5 to < 25 kg/m2), n (%) 16 (18.2)
 Overweight (25 to < 30 kg/m2), n (%) 39 (44.3)
 Obese (≥ 30 kg/m2), n (%) 33 (37.5)
Diabetes, n (%)
 Yes 27 (18.0)
  Type 1 3 (11.1)
  Type 2 24 (88.9)
 No 123 (82.0)
Cardiovascular-related comorbidities, n (%)
 Chronic heart failure 4 (2.7)
 Arrhythmia 4 (2.7)
 Chronic kidney disease (stage II–ESRD), n (%) 14 (9.3)
 Hypertension 67 (44.7)
Cardiovascular event history
 Number of previous events, median (range; IQR)b 1.0 (0–12; 0–1)
 Myocardial infarction, n (%) 42 (28.0)
 Ischemic stroke, n (%) 11 (7.3)
 Hemorrhagic stroke, n (%) 1 (0.7)
 Unstable angina, n (%) 9 (6.0)
 Stable angina, n (%) 25 (16.7)
 Peripheral arterial disease, n (%) 10 (6.7)
Cardiovascular revascularization procedure history, n (%)
 Coronary artery bypass graft 20 (13.3)
 Percutaneous coronary intervention/percutaneous translu-
minal coronary angioplasty
23 (15.3)
 Carotid 4 (2.7)
 Femoral 5 (3.3)
Categorization per NICE/SMC criteria, n (%)
 Primary non-familial hypercholesterolemia or mixed 
dyslipidemia with high risk of cardiovascular disease 
and LDL-C > 4.0 mmol/l
12 (8.0)
 Primary non-familial hypercholesterolemia or mixed dys-
lipidemia with very high risk of cardiovascular disease 
and LDL-C > 3.5 mmol/l
16 (10.7)
 Primary HeFH without cardiovascular disease and 
LDL-C > 5.0 mmol/l
34 (22.7)
 Primary HeFH with cardiovascular disease (either high-
risk or very high risk) and LDL > 3.5 mmol/l
38 (25.3)
BMI body mass index, CV cardiovascular,  CVA  cerebrovascular 
accident,  CVD cardiovascular disease, HeFH heterozygous familial 
hypercholesterolemia, IQR interquartile range, LDL-C low-density 
lipoprotein cholesterol, MI myocardial infarction,  NICE National 
Institute of Health and Care Excellence, PAD peripheral arterial dis-
ease, SMC Scottish Medicines Consortium, SD standard deviation
a Unless otherwise stated; not all variables were available for all 
patients
b Events were defined as the following: myocardial infarction (MI), 
coronary artery by-pass graft (CABG), revascularization (PCI/PTCA, 
carotid or femoral), cerebrovascular accident (ischemic or hemor-
rhagic), unstable angina, and peripheral arterial disease (PAD). All 
data for revascularization procedures were reviewed on a case-by-
case basis, and revascularization procedures (CABG, PCI/PTCA, 
‘revascularization-carotid,’ ‘revascularization-femoral’) that occurred 
within 90 days of a defined CV event (MI, CVA-ischemic, CVA-hem-
orrhagic, unstable angina, PAD) were counted as the same event for 
analysis purposes
c Patients whose baseline LDL-C values were not available to catego-
rize patients
Table 1  (continued)
Variable Cohort 
(N = 150)a
 Did not fit NICE/SMC recommendations 36 (24.0)
 Not  knownc 14 (9.3)
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to 150 mg and then subsequently down-titrated to 75 mg. 
Although not explicitly investigated in this study, it is the 
opinion of the authors that dosing flexibility and ability 
to adjust strength based on response and acceptability are 
important when initiating a new treatment. Additionally, the 
fact that several patients remained on a lower strength of 
alirocumab (despite high LDL-C at initiation) may reflect 
the high level of statin intolerance observed and patient and/
or physician preference in initiating any new medications 
at lower strengths in an attempt to mitigate potential side 
effects. Finally, low rates of alirocumab discontinuation were 
observed; however, this was determined over a relatively 
short follow-up period.
4.1  Limitations
The study was designed to capture data that accurately rep-
resent the real-world UK population receiving alirocumab 
to inform future discussions with HTA bodies. Thus, this 
study was descriptive only, and no formal power calculations 
of outcomes were conducted; nevertheless, observations of 
Table 2  Prior lipid-lowering therapy use for UK patients initiated on 
alirocumab
Variable Cohort 
(N = 150)a
Patients with statin use since diagnosis
 Number of statins used since diagnosis, median 
(range; IQR)
3 (1–5; 2–4)
  1, n (%) 25 (16.7)
  2, n (%) 33 (22.0)
  3, n (%) 41 (27.3)
  4, n (%) 40 (26.7)
  5, n (%) 11 (7.3)
 Patients with known statin intolerance since diagnosis, n (%)
  Intolerant to no statins 27 (18.0)
  Intolerant to ≥ 1 statin 123 (82.0)
  Intolerant to ≥ 2 statins 100 (66.7)
 Patients with lipid-lowering therapy use within 6 months prior to 
alirocumab initiation, n (%)
  None 56 (37.3)
  ≥ 1 lipid-lowering therapy 94 (62.7)
  Statin 63 (42.0)
  Ezetimibe 67 (44.7)
  Fibrates 11 (7.3)
  Otherb 11 (7.3)
 Patients with statin use within 6 months prior to 
alirocumab initiation, n (%)
63
  Atorvastatinc 17 (27.0)
   20 mg 2/17 (11.8)
   40 mg 5/17 (29.4)
   80 mg 7/17 (4.1)
   Other 3/17 (17.6)
  Rosuvastatinc 34 (54.0)
   10 mg 5/34 (14.7)
   20 mg 4/34 (11.8)
   40 mg 11/34 (32.4)
   Other 14/34 (41.2)
  Simvastatin 0 (0.0)
  Pravastatin 6 (9.5)
  Fluvastatin 6 (9.5)
 Statin regimen within 6 months prior to ali-
rocumab initiation, n (%)
63
  Once daily 50 (79.4)
  Twice daily 2 (3.2)
  Weekly 6 (9.5)
  Otherd 5 (7.9)
 Patients receiving high-intensity statin within 
6 months prior to alirocumab initiation, n (%)
41
  Atorvastatin (80 mg) 7 (17.1)
  Atorvastatin (20–80 mg) 14 (34.1)
  Rosuvastatin (10–40 mg) 20 (48.8)
  Simvastatin (80 mg) 0 (0.0)
IQR interquartile range
a Unless otherwise stated; not all variables were available for all 
patients
b Includes cholestyramine (n = 2), colesevelam (n = 2), evolocumab 
(n = 1), omega 3 (n = 4), and not known (n = 2)
c Equivalent daily dose
d Rosuvastatin 5  mg twice weekly (n = 2); rosuvastatin 5  mg three 
times/week (n = 1); rosuvastatin 5 mg regimen, and other (not speci-
fied; n = 2)
e Categories captured for reason for discontinuation were: ‘difficulty 
with dosing,’ ‘due to adverse event,’ ‘due to lack of efficacy,’ and ‘not 
known.’ For brevity, results where no data were present are not shown
Table 2  (continued)
Variable Cohort 
(N = 150)a
 Reason for lipid-lowering therapy discontinua-
tion/dose change prior to alirocumab initiation, 
n (%)e
–
  Statin changes 37
   Lack of efficacy 9 (24.3)
   Difficulty with dosing 7 (18.9)
   Adverse event 17 (45.9)
   Not known 4 (10.8)
  Ezetimibe changes 16
   Lack of efficacy 2 (12.5)
   Difficulty with dosing 3 (18.8)
   Adverse event 8 (50.0)
   Not known 3 (18.8)
  Fibrate changes due to lack of efficacy 3 (100.0)
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potential interest to prescribers and decision-makers have 
been discussed herein.
As with any retrospective observational study based on 
secondary data, interpretation of study end points relies 
on the completeness and quality of the source medical 
records and accuracy of data abstraction from medical 
records available in routine NHS practice. Furthermore, 
retrospective observational studies can be limited by real-
world-related biases with numerous (potentially unmeas-
urable) confounders. Efforts were sought to ameliorate 
these limitations by testing for potential between-center 
bias, recruiting patients in reverse consecutive order, and 
employing source data verification to enable correction of 
abstraction errors.
To minimize bias and to reflect, as accurately as pos-
sible, a cross-section of clinical experience throughout the 
UK, sites were chosen from different geographical loca-
tions across England, Wales, and Scotland that regularly 
prescribed alirocumab. Therefore, the characteristics of 
patients treated with alirocumab at centers that were not 
regular prescribers may be different from those included 
in this study. Additionally, to recruit enough patients, most 
data were derived from the central region of England, where 
alirocumab use has been most prevalent since the imple-
mentation of HTA body recommendations. Demograph-
ics in this area may be different from other UK regions; 
however, patient numbers were too small to establish this. 
Larger studies are required to increase the generalizability 
of the data.
The relatively short follow-up period of 4  months 
was implemented because of the slow uptake of PCSK9i 
observed across the UK [22] and the short time frame 
between publication of HTA body recommendations and 
study recruitment. Longer term follow-up is warranted to 
observe clinical outcomes with alirocumab.
Table 3  Alirocumab prescribing patterns during the post-initiation 
period
IQR interquartile range
a Unless otherwise stated; not all variables were available for all 
patients
b Includes two patients who were subsequently down-titrated to 75 mg
Variable Cohort (N = 150)a
Starting strength of alirocumab, n (%)
 75 mg 108 (72.0)
 150 mg 42 (28.0)
Alirocumab strength change, n (%)
 75 mg → 150 mg 35 (23.3)b
 150 mg → 75 mg 0 (0.0)
 75 mg → 150 mg → 75 mg 2 (1.3)
Time to up-titration of alirocumab, n 35
 Weeks, median (range; IQR) 11.7 (4.0–16.0; 8.0–12.9)
 Alirocumab discontinuation, n (%) 19 (12.7)
 Reason –
  Lack of efficacy 0 (0.0)
  Difficulty with dosing 0 (0.0)
  Adverse event (patient or physician 
reported)
17 (89.5)
  Not known 2 (10.5)
Change in background statin treatment, 
n (%)
42
 No change 34 (81.0)
 Discontinuation 5 (11.9)
 Initiation 3 (7.1)
Change in background ezetimibe treat-
ment, n (%)
60
 No change 56 (93.3)
 Discontinuation 1 (1.7)
 Initiation 3 (5.0)
No change in background fibrate treat-
ment, n (%)
8 (100.0)
Fig. 1  Change in lipid parameters over the post-initiation period. 
HDL-C high-density lipoprotein cholesterol, LDL-C low-density 
lipoprotein cholesterol, TC total cholesterol, TG triglyceride. Bars 
and error bars record the median and interquartile range, respectively. 
Data reported for all patients for whom a paired lipid parameter 
measurement were available before any changes in alirocumab dose
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The study was not statistically powered to estimate effec-
tiveness of alirocumab regarding change in lipid parameters 
and, unexpectedly, paired data were not available for all 
patients, resulting in small sample sizes for evaluation. The 
lack of LDL-C data for some patients was mostly due to con-
current hypertriglyceridemia (> 4.5 mmol/l) ,which would 
confound the calculation of LDL-C via the Friedewald equa-
tion. Additionally, follow-up blood tests in some centers may 
not have been conducted for some patients within 6 months 
of initiation. Furthermore, lipid parameter changes may have 
been confounded by changes to background LLT regimens, 
which we were unable to adjust for given the paucity of 
recorded changes observed in routine clinical practice. Fur-
thermore, treatment adherence with alirocumab was not cap-
tured. Lastly, although reflective of early alirocumab use in 
the UK, lipid parameter changes reported pertain primarily 
to HeFH patients with statin intolerance and limited repre-
sentation from those with primary non-familial hypercho-
lesterolemia or mixed dyslipidemia.
Data regarding individual AE terms, severity grading, and 
their duration were not collected because of the anticipated 
incomplete and inconsistent recording of this information in 
medical records across sites in routine practice. However, the 
safety profile of alirocumab was well described during the 
ODYSSEY clinical trial program [11].
5  Conclusion
Early use of alirocumab predominantly in high-risk patients 
with HeFH and patients with a high level of statin intoler-
ance indicates an unmet need for the treatment of hyperlipi-
demia inadequately controlled with conventional LLT use.
The high degree of alirocumab 75 mg usage suggests that 
two strength flexibility is an important attribute of this novel 
therapeutic option in clinical practice. Additionally, although 
the study was designed to be descriptive only, low discon-
tinuation and clinically significant LDL-C reductions are 
supportive of the utility of alirocumab in clinical practice.
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Table 4  Change in lipid parameters from baseline
HDL-C high-density lipoprotein cholesterol, IQR interquartile range, LDL-C low-density lipoprotein cholesterol, TC total cholesterol, TG tri-
glyceride
a All patients for whom a paired lipid parameter measurement was available before any changes in alirocumab dose
b Patients who started on the 75 mg strength of alirocumab and remained on 75 mg at the time the post-initiation lipid parameter measurement 
was taken
c Patients who started on the 150 mg strength of alirocumab and remained on 150 mg at the time the post-initiation lipid parameter measurement 
was taken
The summary measures reported represent the median (IQR) of percentage changes at a patient level. The Wilcoxon signed rank test was used to 
generate P values
LDL-C Non-HDL-C TC TG HDL-C
Alla
 n 94 80 114 110 112
 Median (IQR) change 
from baseline (%)
− 53.6  
(− 62.9 to − 34.9)
–45.7  
(–53.8 to –30.1)
− 34.7  
(− 42.8 to − 23.5)
− 9.8  
(− 29.6 to 15.1)
4.9  
(− 6.3 to 13.7)
 P value < 0.001 < 0.001 < 0.001 0.004 0.002
75 mgb
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 Median (IQR) change 
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150 mgc
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 Median (IQR) change 
from baseline (%)
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(− 57.3 to − 39.4)
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